Stoke Therapeutics Earnings Estimate
| STOK Stock | USD 31.63 0.77 2.38% |
Stoke Therapeutics Earnings Estimation Breakdown
The calculation of Stoke Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Stoke Therapeutics is estimated to be -0.7764 with the future projection ranging from a low of -0.875 to a high of -0.6975. Please be aware that this consensus of annual earnings estimates for Stoke Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.88 Lowest | Expected EPS | -0.7 Highest |
Stoke Therapeutics Earnings Projection Consensus
Suppose the current estimates of Stoke Therapeutics' value are higher than the current market price of the Stoke Therapeutics stock. In this case, investors may conclude that Stoke Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Stoke Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 11 | 41.27% | 0.0 | -0.7764 | 0.68 |
Stoke Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Stoke Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Stoke Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Stoke Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Stoke Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Stoke Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Stoke Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Stoke Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Stoke Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-04 | 2025-09-30 | -0.58 | -0.65 | -0.07 | 12 | ||
2025-08-12 | 2025-06-30 | -0.5 | -0.4 | 0.1 | 20 | ||
2025-05-05 | 2025-03-31 | -0.0905 | 1.9 | 1.9905 | 2199 | ||
2025-03-24 | 2024-12-31 | -0.5302 | -0.18 | 0.3502 | 66 | ||
2024-11-05 | 2024-09-30 | -0.53 | -0.4691 | 0.0609 | 11 | ||
2024-08-07 | 2024-06-30 | -0.56 | -0.46 | 0.1 | 17 | ||
2024-05-06 | 2024-03-31 | -0.61 | -0.57 | 0.04 | 6 | ||
2024-03-25 | 2023-12-31 | -0.63 | -0.6 | 0.03 | 4 | ||
2023-11-07 | 2023-09-30 | -0.63 | -0.55 | 0.08 | 12 | ||
2023-08-07 | 2023-06-30 | -0.64 | -0.69 | -0.05 | 7 | ||
2023-05-04 | 2023-03-31 | -0.7 | -0.53 | 0.17 | 24 | ||
2023-03-06 | 2022-12-31 | -0.7 | -0.65 | 0.05 | 7 | ||
2022-11-14 | 2022-09-30 | -0.68 | -0.66 | 0.02 | 2 | ||
2022-08-08 | 2022-06-30 | -0.69 | -0.63 | 0.06 | 8 | ||
2022-05-10 | 2022-03-31 | 0.36 | -0.66 | -1.02 | 283 | ||
2022-03-10 | 2021-12-31 | -0.62 | -0.66 | -0.04 | 6 | ||
2021-11-08 | 2021-09-30 | -0.59 | -0.61 | -0.02 | 3 | ||
2021-08-10 | 2021-06-30 | -0.47 | -0.6 | -0.13 | 27 | ||
2021-05-10 | 2021-03-31 | -0.44 | -0.46 | -0.02 | 4 | ||
2021-03-09 | 2020-12-31 | -0.42 | -0.42 | 0.0 | 0 | ||
2020-11-12 | 2020-09-30 | -0.41 | -0.41 | 0.0 | 0 | ||
2020-08-10 | 2020-06-30 | -0.35 | -0.39 | -0.04 | 11 | ||
2020-05-15 | 2020-03-31 | -0.36 | -0.34 | 0.02 | 5 | ||
2020-02-23 | 2019-12-31 | -0.31 | -0.09 | 0.22 | 70 | ||
2019-11-12 | 2019-09-30 | -0.27 | -0.26 | 0.01 | 3 | ||
2019-08-14 | 2019-06-30 | -0.96 | -1.54 | -0.58 | 60 | ||
2019-06-19 | 2019-03-31 | 0 | -6.89 | -6.89 | 0 |
About Stoke Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Stoke Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Stoke Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Stoke Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -441.7 M | -419.7 M | |
| Retained Earnings Total Equity | -267.4 M | -254.1 M | |
| Earnings Yield | (0.17) | (0.18) | |
| Price Earnings Ratio | (6.03) | (6.33) | |
| Price Earnings To Growth Ratio | 0.25 | 0.24 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 1.172 | Return On Assets | Return On Equity |
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.